Last reviewed · How we verify

Ethazole — Competitive Intelligence Brief

Ethazole (SULFAETHIDOLE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sulfaethidole. Area: Other.

phase 2 sulfaethidole RAC-alpha serine/threonine-protein kinase Other Small molecule Live · refreshed every 30 min

Target snapshot

Ethazole (SULFAETHIDOLE). Ethazole works by inhibiting the RAC-alpha serine/threonine-protein kinase enzyme, which plays a crucial role in cell signaling pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ethazole TARGET SULFAETHIDOLE phase 2 sulfaethidole RAC-alpha serine/threonine-protein kinase
Impavido MILTEFOSINE Knight Theraps marketed Antileishmanial [EPC] RAC-alpha serine/threonine-protein kinase 2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sulfaethidole class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ethazole — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfaethidole. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing